Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin's lymphoma patients with an interim PET deauville score of 4

View Full Paper
Ask AI
Bookmark
Share

Authors

NNNelson Inácio Pinto NetoANArata NishimotoCPCarolina Pereira

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reveals no survival benefit of BEACOP-DAC over ABVD in Hodgkin's lymphoma patients.

Key Points

  • To evaluate the effectiveness of dose escalation to BEACOP-DAC versus continuing ABVD in patients with Hodgkin's lymphoma and a Deauville score of 4.
  • Retrospective cohort study of cHL patients from January 2019 to January 2025.
  • Included patients with an interim PET Deauville score of 4.
  • Compared progression-free survival and complete response rates between ABVD and BEACOP-DAC treatment groups.
  • 31 out of 218 patients had a Deauville score of 4 on interim PET.
  • Median progression-free survival was 25 months for BEACOP-DAC and not reached for ABVD/AVD.
  • Complete response rates were 69.2% for BEACOP-DAC versus 61.1% for ABVD/AVD, showing no significant difference.

Cite This Study

Neto et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d340https://doi.org/10.1182/blood-2025-1854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305)2024 · 4 citations
  2. 2Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD2024 · 4 citations
  3. 3Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group2025
  4. 4Long‐term follow‐up of <scp>PET</scp> / <scp>CT</scp> ‐adapted therapy after three cycles of <scp>ABVD</scp> for all stages of classic Hodgkin lymphoma: Results of the <scp>GATLA LH</scp> ‐05 trial2026
  5. 5Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma2026